Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial

Overview of attention for article published in Frontiers in oncology, December 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 4 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 18,759 followers.

RT @FrontOncology: New research: Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylate…

15 Dec 2023

Reply Repost Favourite

New research: Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial: Introduction Drug repurposing is a promising strategy to… https://t.co/X7sY

15 Dec 2023

Reply Repost Favourite

RT @polistudium: We are thrilled to share the latest findings from a recently published Phase II clinical trial in which we had the privile…

15 Dec 2023

Reply Repost Favourite

We are thrilled to share the latest findings from a recently published Phase II clinical trial in which we had the privilege of collaborating on the paper writing. You can find the study here https://t.co/u7xQkblWCJ #medicalwriting #glioblastoma #clinica

15 Dec 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.